Virta Health is now expanding its services by prescribing GLP-1 medications, including Ozempic, to treat obesity alongside its established diabetes-reversal program. Known for its effective diabetes management through personalized low-carb diet plans, Virta aims to pair medication with nutritional support to help patients lose weight sustainably. With over $100 million in annual recurring revenue and projected rapid growth, the company is on track for profitability by 2025 and a potential IPO in the future.
Virta now is positioning itself as a responsible prescriber for employers who want to manage the costs of covering those medications.
Virta released a study in February 2024 showing its program can help diabetes patients maintain their weight loss after they stop taking GLP-1s.
The company is now bringing in more than $100 million in annual recurring revenue, a 60% year-over-year increase.
Virta expects even faster growth in 2025 as its weight-loss business accelerates.
Collection
[
|
...
]